Delving into the Latest Updates on Eluxadoline with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

Eluxadoline (USAN), Mu Delta, TRUBERZI

+ [2]

Target

δ opioid receptor x κ opioid receptor x μ opioid receptor

Action

antagonists, agonists

Mechanism

δ opioid receptor antagonists(δ-opioid receptor antagonists), κ opioid receptor agonists(Kappa opioid receptor agonists), μ opioid receptor agonists(Mu opioid receptor agonists)

Therapeutic Areas

Digestive System DisordersOther Diseases

Active Indication

Irritable bowel syndrome with diarrheaIrritable Bowel SyndromeDiarrhea

Inactive Indication

Diabetes MellitusDiabetes Mellitus, Type 1Fecal Incontinence+ [2]

Originator Organization

Actavis

Active Organization

AbbVie, Inc.Allergan Pharma Co.Allergan, Inc. (Canada)

Inactive Organization

Allergan Pharmaceuticals International Ltd.Allergan UC

License Organization

Janssen Pharmaceuticals, Inc.

Forest Laboratories LLC

Furiex Pharmaceuticals, Inc.

Drug Highest PhaseApproved

First Approval Date

United States (27 May 2015),

Irritable Bowel Syndrome

RegulationFast Track (United States)

Login to view timeline

Structure/Sequence

Molecular FormulaC32H35N5O5

InChIKeyQFNHIDANIVGXPE-FNZWTVRRSA-N

CAS Registry864821-90-9

Diabetes is a chronic disease that affects a large part of the United States population. The majority of patients with diabetes will experience gastrointestinal symptoms. One of the most troublesome gastrointestinal symptoms that diabetes can cause is diarrhea, otherwise known as "Diabetic Diarrhea." This occurs because diabetes does damage to nerves that control the gut and prevent it from functioning normally. Currently, there are only several medications used to treat the symptoms of Diabetic Diarrhea, but many of these medications have serious side effects or do not work well.
We are investigating the drug eluxadoline for the treatment of Diabetic Diarrhea. Eluxadoline is a gut-specific medication that is FDA approved to treat diarrhea related to irritable bowel syndrome (IBS-D). Our hypothesis is eluxadoline will safely and successfully reduce diarrhea symptoms (number of stools and less liquid stools) and improve the quality of life in patients with Diabetic Diarrhea when compared with placebo. Each patient with Diabetic Diarrhea who participates will take both eluxadoline and a placebo drug at separate times over a period of several months as part of a crossover study design. While on each medication, eluxadoline or placebo, the participants will keep a diary of symptoms and will be followed by the medical team through a combination of office visits and questionnaires. There will be five planned office visits and intermittent phone calls (questionnaires, surveys) over the 140-day study period. Participants will not be permitted to use any other anti-diarrhea medication during the study period and will continue on medication for management of their diabetes.

Start Date01 Jul 2022

Sponsor / Collaborator

Temple University Graduate School

[+1]

NCT04880876

/ Enrolling by invitationPhase 3

A Phase 3, Long-term Safety Study of Oral Eluxadoline Administered to Pediatric Participants With Irritable Bowel Syndrome With Diarrhea (IBS-D)

This study will assess the long-term safety of oral Eluxadoline administered to pediatric participants with IBS-D who have completed study intervention in the Phase 2 study 3030-202-002 or the Phase 3 study 3030-303-002.

Start Date13 Aug 2021

Sponsor / Collaborator

AbbVie, Inc.

NCT03489265

/ WithdrawnPhase 2IIT

Treatment of Diarrhea-Associated Fecal Incontinence With Eluxadoline

Accidental bowel leakage (fecal incontinence) increases in people who have diarrhea and sensations of urgency to have a bowel movement. Drugs such as loperamide (Imodium) that reduce diarrhea improve accidental bowel leakage, but loperamide has disadvantages: it is difficult to find a dose that does not cause constipation, and it does not reduce urge sensations. Eluxadoline is a new drug that is effective for reducing diarrhea, abdominal pain, and urgency in patients with irritable bowel syndrome, and it may be less likely than loperamide to cause severe constipation. Therefore, eluxadoline may help patients manage accidental bowel leakage caused by diarrhea. The chemical name for Viberzi® is eluxadoline.
The primary aims of this study are to find out if eluxadoline at a dose of 100 mg orally twice a day will reduce the average number of days the patient has accidental bowel leakage, and to see if the rate of accidental bowel leakage increases when the patient stops taking eluxadoline. Additional goals are to find out if eluxadoline decreases diarrhea and urge sensations.
This is a small (pilot) study to show whether eluxadoline is an effective way of treating accidental bowel leakage. If the study shows this, a larger study will be needed. There are three phases to this 12-week study: (1) A two-week run-in period to see if the patient meets the inclusion criteria. (2) Two months for treatment including one month on eluxadoline and one on placebo (sugar pills) twice a day. (3) A two-week follow-up to see what happens when you stop taking eluxadoline.
To participate in the study, patients should be aged 18 or older. Patients with inflammatory bowel disease, anal fissures, or congenital malformations will be excluded.
The primary outcome is the average number of days per week with any solid or liquid bowel accidents. Additional information includes: (1) Number of days per week the patient takes loperamide, (2) days per week with loose or watery stools, (3) days per week with moderate to strong urge sensations, and (4) questionnaires to measure the severity of accidental bowel leakage, quality of life, anxiety, and depression. There will be up to 38 patients in the study.

Start Date01 Apr 2019

Sponsor / Collaborator

The University of North Carolina at Chapel Hill

[+1]

100 Clinical Results associated with Eluxadoline

Login to view more data

100 Translational Medicine associated with Eluxadoline

Login to view more data

100 Patents (Medical) associated with Eluxadoline

Login to view more data

140

Literatures (Medical) associated with Eluxadoline

02 Sep 2026·Expert Opinion On Drug Safety

Diarrhea-predominant irritable bowel syndrome treatment options eluxadoline, rifaximin, and alosetron: analysis of the FDA adverse event reporting system (FAERS) database

Article

Author: Andrews, Michael B. ; Adler, Douglas G.

BACKGROUND:

Adverse events (AEs) suspected to be associated with the three FDA approved medications (eluxadoline, rifaximin, and alosetron) for diarrhea-predominant irritable bowel syndrome (IBS-D) were examined.

RESEARCH DESIGN AND METHODS:

We analyzed all reports in the FDA Adverse Event Reporting System (FAERS) database from each medication's date of FDA approval through 30 June 2024. Reports were excluded if they contained other suspected medications or had a reason for use outside of IBS and/or diarrhea.

RESULTS:

Eluxadoline was associated with 1,002 AEs, most commonly abdominal pain (n = 257, 17.0%) and uniquely pancreatitis (n = 174, 11.5%) and sphincter of Oddi dysfunction (n = 39, 2.6%). Rifaximin was associated with 652 AEs, most commonly abdominal pain (n = 64, 7.6%) and uniquely C.difficile and bacterial overgrowth (n = 3, 0.4% each). Alosetron was associated with 3,832AEs, most commonly constipation (n = 2,007, 23.1%) and uniquely colitis (n = 235,2.7%), ischemic colitis (n = 140, 1.6%), obstruction (n = 110, 1.3%), and perforation (n = 26, 0.3%).

CONCLUSIONS:

Our analysis of the FAERS database showed frequent reports of abdominal pain, constipation, and nausea/vomiting related to the three FDA approved medications for IBS-D. Each raised concerns for distinct and serious AEs including pancreatitis (eluxadoline), C.difficile infection (rifaximin), ischemic colitis (alosetron), and intestinal obstruction/perforation (alosetron).

01 Mar 2026·AMERICAN JOURNAL OF GASTROENTEROLOGY

The Safety of Pharmacotherapy for Irritable Bowel Syndrome: A Systematic Review and Meta-Analysis

Review

Author: Busam, Jonathan A. ; Pimentel, Mark ; Rezaie, Ali ; Joo, LiJin ; Marshall, Caroline ; Batta, Nisha ; Shah, Eric D.

INTRODUCTION::

Understanding the safety of pharmacotherapy for irritable bowel syndrome (IBS) enables individuals to make informed treatment decisions. While many studies include the number needed to treat to highlight therapeutic benefits, adding the number needed to harm (NNH), a measure we evaluate herein, could enable more comprehensive risk-benefit assessments.

METHODS::

PubMed, Web of Science, and Cochrane databases were searched through October 2024. Clinical trials investigating IBS pharmacotherapies including discontinuation rates because of adverse events (AEs) were included. Data were pooled using a random-effects model. The primary outcome was NNH for each pharmacotherapy, defined as the reciprocal of the absolute difference in risk of AEs leading to treatment discontinuation between the experimental and placebo groups. Secondary outcomes included the relative risk of withdrawing because of an AE and the most common AEs for each drug.

RESULTS::

Fifty-four trials met inclusion criteria. For constipation-predominant IBS pharmacotherapies, the NNH for linaclotide, lubiprostone, plecanatide, tegaserod, and tenapanor was 35 ( P < 0.01), 53 ( P = 0.59), 59 ( P < 0.01), 58 ( P = 0.03), and 16 ( P < 0.01), respectively. For diarrhea-predominant IBS pharmacotherapies, the NNH for alosetron and eluxadoline was 14 ( P < 0.01) and 32 ( P < 0.01) whereas the NNH for both rifaximin and ramosetron was a negative, although statistically insignificant, value. For IBS global symptom pharmacotherapies, the tricyclics, the NNH was 24 ( P < 0.01). Many AEs were transient without long-term sequela.

DISCUSSION::

Among pharmacotherapies for IBS, tricyclics (especially at elevated doses), tenapanor, and alosetron have the highest absolute risk of discontinuation because of an AE when compared with rifaximin, the safest pharmacotherapy studied.

04 Mar 2025·Expert Review of Gastroenterology & Hepatology

An evidence-based update on the diagnosis and management of irritable bowel syndrome

Review

Author: Black, Christopher J. ; Ford, Alexander C.

INTRODUCTION:

Irritable bowel syndrome (IBS) is a disorder of gut-brain interaction affecting 5% of the population. The cardinal symptoms are abdominal pain and altered stool form or frequency.

AREAS COVERED:

Diagnosis and management of IBS. We searched the literature for diagnostic accuracy studies, randomized controlled trials, and meta-analyses. A positive diagnosis of IBS, alongside testing to exclude celiac disease, is recommended. Exhaustive investigation has a low yield. Patients should be offered traditional dietary advice. If response is incomplete, specialist dietetic guidance should be considered. Probiotics may be beneficial, but quality of evidence is poor. First-line treatment of constipation is with laxatives, with secretagogues used where these are ineffective. Anti-diarrheal drugs should be used first-line for diarrhea, with second-line drugs including 5-hydroxytryptamine-3 antagonists, eluxadoline, or rifaximin, where available. First-line treatment of abdominal pain should be with antispasmodics, with gut-brain neuromodulators prescribed second-line. Low-dose tricyclic antidepressants, such as amitriptyline, are preferred. Brain-gut behavioral therapies are effective and have evidence for efficacy in patients refractory to standard therapies.

EXPERT OPINION:

Despite substantial advances, there remains scope for improvement in terms of both the diagnosis and management of IBS. Reinforcement of positive diagnostic strategies for the condition and novel treatment paradigms are required.

11

News (Medical) associated with Eluxadoline

19 Mar 2025

·pharma.economictimes.indiatimes.com

Zydus Lifesciences shares rally 3% after FDA approval for prostate cancer drug

Zydus Lifesciences shares rallied 3 per cent in early trade to a high of Rs 930.60 on the BSE on Wednesday after the company secured final approval from the US Food and Drug Administration ( USFDA ) to manufacture a generic version of Apalutamide tablets, used to treat prostate cancer. The approval covers Apalutamide tablets of 60 mg strength, the company said in a regulatory filing. The drug will be manufactured at Zydus Lifesciences ' SEZ facility in Ahmedabad. Apalutamide, an androgen receptor inhibitor, is prescribed for patients with metastatic castration-sensitive prostate cancer. It had annual US sales of $1,099.8 million, according to IQVIA MAT January 2025 data. Last week, Zydus Lifesciences also received USFDA approval to manufacture Eluxadoline tablets (75 mg and 100 mg), used to treat irritable bowel syndrome with diarrhea in adults. These will also be produced at the SEZ facility in Ahmedabad. Zydus was among the first to file an Abbreviated New Drug Application (ANDA) with a Paragraph IV certification for Eluxadoline tablets. This approval grants the company 180 days of shared generic exclusivity for the drug. Zydus Life shares target price As per Trendlyne data, the average target price of the stock is Rs 1,064, which shows an upside of 18% from the current market prices. The consensus recommendation from 31 analysts for the stock is a 'Hold'. Technically, the stock's relative strength index (RSI) is at 48. According to Trendlyne, an RSI below 30 is considered oversold, while above 70 indicates overbought conditions. Additionally, the MACD is at -16.1, which is below its center line, this is a bearish indicator. The stock is trading below its 30-day, 50-day, 100-day, 150-day, and 200-day simple moving averages (SMAs) but remains above its 5-day, 10-day, and 20-day SMAs. Zydus Life shares performance On Tuesday, Zydus Life shares closed at Rs 903.1, up 1.1 per cent on the BSE, while the benchmark Sensex surged 1.53%. The stock has declined 7 per cent year-to-date and 16 per cent in the last six months. The company’s market capitalization stands at Rs 90,872 crore.

Drug ApprovalAccelerated Approval

16 Mar 2025

·pharma.economictimes.indiatimes.com

Zydus diarrhoea generic secures FDA final nod

Ahmedabad: Zydus Lifesciences , announced that the United States Food and Drug Administration (FDA) has given its final approval to market and manufacture eluxadoline tablets . Eluxadoline, is a mu-opioid receptor agonist, indicated in adults for the treatment of irritable bowel syndrome with diarrhoea (IBS-D). The generic medication , will be manufactured at company’s Ahmedabad facility and will produce them in the dosage strength of 75 and 100 mg. As per IQVIA figures in the last annual till January 2025, eluxadoline tablets had annual sales of $243.7 million in the United States. The Indian drug maker claims itself as the first ANDA applicants to submit a substantially complete ANDA with a paragraph IV certification and is eligible for 180 days of shared generic drug exclusivity for the medication. In a stock exchange filing the company said that, post this approval the group now has 419 approvals and has so far filed 483 ANDAs since the commencement of the filing process in FY 2003-04. By Online Bureau ,

Drug Approval

04 Jun 2024

·www.prnewswire.com

Analysis Group Researchers Suggest a Novel Approach to Measuring Real-World Treatment Effectiveness for Irritable Bowel Syndrome with Diarrhea

BOSTON, June 4, 2024 /PRNewswire/ -- Researchers from Analysis Group, a global leader in health economics and outcomes research (HEOR), have coauthored a study detailing how treatment-free intervals (TFIs) can be an effective surrogate in retrospective data analyses for understanding therapy effectiveness for conditions that present multifaceted symptoms across widely divergent patient populations, such as irritable bowel syndrome with diarrhea (IBS-D). The study, published in the journal Advances in Therapy, is the first to use TFIs to assess real-world IBS-D therapy response, using two of the most commonly prescribed treatments in the US: rifaximin and eluxadoline. While the Food and Drug Administration (FDA) recommends using a five-item opinion-based questionnaire to measure patient-reported outcomes (PROs) that capture clinically important signs and symptoms to define treatment effects in clinical trials, it is challenging to apply this method to evaluate real-world outcomes in retrospective studies. The difficulty lies in the complex presentation of IBS-D, a common, chronic, relapsing, and potentially severe disorder of gut–brain interaction characterized by troublesome symptoms such as abdominal pain, diarrhea, fecal urgency, and bloating. To overcome these challenges, study investigators analyzed US commercial claims data for 9,255 IBS-D patients receiving one of the two treatments over the course of one year. The researchers focused on patients' TFI patterns – the length of time a patient remains off treatment after a course of therapy. Patient characteristics included age, sex, health plan type, region, and provider specialty, as of the index date. During baseline, medically relevant comorbidities (both gastrointestinal- and mental health–related), procedures (e.g., anesthesia, surgery, radiation services), and treatments were reported. Investigators specifically examined the duration of the index treatment, the number of prescription fills, and all-cause health care costs among adult patients with IBS-D treated with rifaximin or eluxadoline. The researchers concluded that TFIs may be a meaningful proxy for measuring treatment effectiveness in IBS-D. Using this method, they also found that patients treated with rifaximin had longer TFIs and lower health care costs than patients treated with eluxadoline. "The challenges of studying IBS-D are similar in many ways to those faced with oncology, where important treatment goals include medication-free periods associated with symptom control, especially when there is a treatment-related toxicity or financial burden associated with treatment changes or combination therapy," said study investigator Annie Guérin, a Managing Principal with Analysis Group. "Our approach to using TFIs was based on the proven strategies used in oncology, where patients value treatment-free periods because they are associated with improved health-related quality of life." The study, "Treatment-Free Interval: A Novel Approach to Assessing Real-World Treatment Effectiveness and Economic Impact Among Patients with Irritable Bowel Syndrome with Diarrhea," was published in April in Advances in Therapy. In addition to Ms. Guérin, investigators included Vice President Patrick S. Gagnon, Associate Rebecca Bungay, and Senior Research Professional Remi Bellefleur of Analysis Group; Brian E. Lacy of Mayo Clinic; Zeev Heimanson of Salix Pharmaceuticals; Brock Bumpass, Danellys Borroto, and Ankur A. Dashputre of Bausch Health; and George Joseph of BioNTech US. Funding was provided by Bausch Health. To learn more about Analysis Group's HEOR capabilities, visit About Analysis Group's HEOR, Epidemiology & Market Access Practice Founded in 1981, Analysis Group is one of the largest international economics consulting firms, with more than 1,200 professionals across 14 offices. Analysis Group's health care experts apply analytical expertise to health economics and outcomes research (HEOR), clinical research, market access and commercial strategy, and health care policy engagements, as well as drug safety-related engagements in epidemiology. Analysis Group's internal experts, together with our network of affiliated experts from academia, industry, and government, provide our clients with exceptional breadth and depth of expertise and end-to-end consulting services globally. Contact: Analysis Group Eric Seymour, +1 978 273 6049 [email protected] SOURCE Analysis Group

Radiation TherapyClinical ResultClinical Study

100 Deals associated with Eluxadoline

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D10403	Eluxadoline	A07DA06	DB09272

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Irritable bowel syndrome with diarrhea	European Union	Allergan Pharmaceuticals International Ltd.	19 Sep 2016
Irritable bowel syndrome with diarrhea	Iceland	Allergan Pharmaceuticals International Ltd.	19 Sep 2016
Irritable bowel syndrome with diarrhea	Liechtenstein	Allergan Pharmaceuticals International Ltd.	19 Sep 2016
Irritable bowel syndrome with diarrhea	Norway	Allergan Pharmaceuticals International Ltd.	19 Sep 2016
Irritable Bowel Syndrome	United States	AbbVie, Inc.	27 May 2015

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Diabetes Mellitus	Phase 3	United States	Allergan UC	01 Jul 2022
Diabetes Mellitus, Type 1	Phase 3	United States	Allergan UC	01 Jul 2022
Diarrhea	Phase 3	United States	Allergan UC	01 Jul 2022
Fecal Incontinence	Phase 2	-	Allergan UC	01 Apr 2019
Intestinal Fistula	Phase 2	-	Allergan UC	01 Apr 2019
Urinary Incontinence, Urge	Phase 2	-	Allergan UC	01 Apr 2019

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


DDW2025	Not Applicable	Irritable bowel syndrome with diarrhea	3,655	Eluxadoline	wxppvgvmah(eiifxbuusc) = Eluxadoline was associated with 1,002 AEs, most commonly abdominal pain (n=257, 17.0%) and uniquely pancreatitis (n=174, 11.5%) and sphincter of Oddi dysfunction (n=39, 2.6%). Rifaximin was associated with 652 AEs, most commonly abdominal pain (n=64, 7.6%) and uniquely C. difficile and bacterial overgrowth (n=3, 0.4% each). Alosetron was associated with 3,832 AEs, most commonly constipation (n=2,007, 23.1%) and uniquely colitis (n=235, 2.7%), ischemic colitis (n=140, 1.6%), obstruction (n=110, 1.3%), and perforation (n=26, 0.3%). cumiqtrnvh (txdepkndst )	Negative	03 May 2025
				Rifaximin
NCT03441581 (3030-401-002, CTgov)	Phase 4	Irritable bowel syndrome with diarrhea \| Bile acid malabsorption	24	Eluxadoline (Eluxadoline 100 mg With BAM)	tdjrirdfqf(ngzthlmish) = zysylsmkfz vvugyjfrts (whjlpayvlj, 0.639) View more	-	19 May 2021
				Eluxadoline (Eluxadoline 100 mg Without BAM)	tdjrirdfqf(ngzthlmish) = azmbydsbfc vvugyjfrts (whjlpayvlj, 0.777) View more
NCT01130272 (CTgov)	Phase 2	Diarrhea \| Irritable Bowel Syndrome	807	Eluxadoline (Eluxadoline 5 mg)	mxbzvaocqd = qbvyleqtwy ytbyeoofow (vndhcjhayl, mqcvrzntnv - ilypfqrtvz) View more	-	22 Oct 2019
				Eluxadoline (Eluxadoline 25 mg)	mxbzvaocqd = sdecrflapq ytbyeoofow (vndhcjhayl, qvhfzcekby - nctwfcyvhn) View more
NCT02959983 (RELIEF, Pubmed \| Am J Gastroenterol) Manual	Phase 4	Diarrhea \| Irritable Bowel Syndrome	346	Eluxadoline	kdswyqwnrf(ueykdenyvf) = uonyrytuja hjfuiwbxdr (rrjxgnidrt ) View more	Positive	01 Sep 2019
				Placebo	kdswyqwnrf(ueykdenyvf) = gwtfhrmkcp hjfuiwbxdr (rrjxgnidrt ) View more
NCT02959983 (RELIEF, CTgov)	Phase 4	Irritable bowel syndrome with diarrhea \| Diarrhea	346	Eluxadoline (Eluxadoline)	ixggykflzf = rjxpmevvpp anvyhmeisf (pzkckprxjd, ipxaemvdiv - bnzalqucnm) View more	-	15 Feb 2019
				Placebo (Placebo)	ixggykflzf = cxzaghplmp anvyhmeisf (pzkckprxjd, gfxplyopum - eeevdqramb) View more
NCT01553591 (CTgov)	Phase 3	Irritable bowel syndrome with diarrhea	1,282	Eluxadoline (Eluxadoline 75 mg)	ddekyqqoul = tdqhidihwv ugnkvxhqaz (sqivjuuzbl, jjjitxdqrm - rtjobtbxxk) View more	-	04 Sep 2018
				Eluxadoline (Eluxadoline 100 mg)	ddekyqqoul = ubsbcnqpll ugnkvxhqaz (sqivjuuzbl, erzgdwqpfa - robqtxlrzn) View more
NCT01553747 (CTgov)	Phase 3	Irritable bowel syndrome with diarrhea	1,146	Eluxadoline (Eluxadoline 75 mg)	lliyqhlpyo = gixhbiboct ytdrjacsef (aykogmdpiq, rvkmssxbla - hrolljtxdb) View more	-	30 Jul 2018
				Eluxadoline (Eluxadoline 100 mg)	lliyqhlpyo = ewssmamhlm ytdrjacsef (aykogmdpiq, adzulvuihq - uslpbripsg) View more
UEGW2017	Not Applicable	Irritable bowel syndrome with diarrhea	-	Eluxadoline 75 mg	rianhtwcic(duvmtkhlio) = tguiohtmjf avtkbmxqqy (fjjzlelmmt )	-	01 Oct 2017
				Eluxadoline 100 mg	rianhtwcic(duvmtkhlio) = rzsxoahmnu avtkbmxqqy (fjjzlelmmt )
UEGW2016	Not Applicable	Irritable Bowel Syndrome	-	Eluxadoline 75 mg	dfoyahmogo(ndeauinmxy) = djfwtokwok uqtktuewzv (jqpwmbiwim ) View more	-	01 Oct 2016
				Eluxadoline 100 mg	dfoyahmogo(ndeauinmxy) = tjevsgwfoz uqtktuewzv (jqpwmbiwim ) View more
NCT01553591 \| NCT01553747 (IBS-3001 and IBS-3002, Pubmed \| N Engl J Med)	Phase 3	Irritable bowel syndrome with diarrhea	2,427	Eluxadoline 75 mg	nxjopelhai(tpibxxqgku) = jtopuilqyp gspgruzgvz (lrgwrotied ) View more	-	21 Jan 2016
				Eluxadoline 100 mg	nxjopelhai(tpibxxqgku) = cpyuqsvxae gspgruzgvz (lrgwrotied ) View more